- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.03. | Novo adds to obesity drug pipeline via $200M deal with China-based biotech | ||
| 24.03. | Biogen plots new global headquarters in Kendall Square | ||
| 24.03. | Tempero Bio gets $70M to advance substance abuse treatment | ||
| 24.03. | Accelerate oncology drug development: A data-driven approach to clinical decisions | ||
| 24.03. | Leveraging clinical and financial data sets to guide investment strategies in 2025's biopharma market | ||
| 21.03. | Optum Rx is reforming how it pays pharmacies | ||
| 21.03. | Delayed CDC meeting on vaccines is rescheduled to April | ||
| 21.03. | AstraZeneca deepens China investment; Editas loses CFO to Dyne | ||
| 21.03. | J&J boosts US manufacturing as big pharma reshores | ||
| 21.03. | Alnylam prices heart drug at premium to rivals | ||
| 20.03. | Alnylam drug gets long-awaited FDA approval in deadly heart disease | ||
| 20.03. | Novartis builds case for new SMA gene therapy | ||
| 20.03. | Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease | ||
| 19.03. | Optum Rx says it will eliminate some prior authorization requirements | ||
| 19.03. | Immunovant claims study success for immune disease drug but holds off on submission | ||
| 19.03. | Cargo shelves cell therapy research and lays off almost all staff | ||
| 18.03. | Sofinnova's latest biotech fund sprouts three new startups | ||
| 18.03. | Prime sets sights on liver, lung disease as next target for its gene editing tech | ||
| 18.03. | Stoke CEO exits; Medicare drug price talks advance | ||
| 18.03. | Duchenne patient dies after receiving Sarepta gene therapy | ||
| 18.03. | Arbor raises $74M amid genetic medicine's funding slump | ||
| 17.03. | Taiho buys Swiss biotech and its ADC tech for $400M | ||
| 17.03. | Orca Bio to seek approval of T cell transplant after positive trial data | ||
| 17.03. | AstraZeneca adds 'in vivo' cell therapy capabilities with EsoBiotech deal | ||
| 17.03. | Latigo raises $150M to get non-opioid pain drugs through key tests |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
